Rajesh R. Tampi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rajesh R. Tampi has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Deena J. Tampi
Behavioral Health Advisory Group, 259 Nassau Street, Suite2 #386, Princeton, NJ 08542, USA
15 shared publicationsPallavi Joshi
Psychiatry Department, Banner University Medical Center, and University of Arizona College of Medicine, Phoenix, AZ, USA
14 shared publicationsDeena J Tampi
Behav Hlth Advisory Grp, Princeton, NJ USA
13 shared publicationsSilpa Balachandran
Case Western Reserve University School of Medicine, Department of Psychiatry, Cleveland, OH 44109, United States
9 shared publicationsJuan Young
Department of Psychiatry Case Western Reserve University MetroHealth Program Cleveland, Ohio, USA
7 shared publicationsPadmapriya Marpuri
Frontier Psychiatry, Billings, USA
7 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in International Psychogeriatrics
- p. 100306
Dementias: From assessment to caregiving
- 29 October 2026
- Published by Elsevier in International Psychogeriatrics
- p. 100306
Open AccessDementias: From assessment to caregiving
- Open Access
- 24 June 2026
- Published by Elsevier in JAACAP Open
- Vol. 4 (5) , 823-832
Suicidality-Related Emergency Department Visits Among US Children and Adolescents, 2016-2022
- 24 June 2026
- Published by Elsevier in JAACAP Open
- Vol. 4 (5) , 823-832
Open AccessSuicidality-Related Emergency Department Visits Among US Children and Adolescents, 2016-2022
- 16 June 2026
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (11) , 1447-1449
Anxiety in Dementia With Lewy Bodies
- 16 June 2026
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (11) , 1447-1449
Anxiety in Dementia With Lewy Bodies
- 15 November 2025
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (2) , 180-182
Dronabinol for Agitation in Alzheimer’s Disease
- 15 November 2025
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (2) , 180-182
Dronabinol for Agitation in Alzheimer’s Disease
- Open Access
- 18 October 2025
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 16
The evidence for ketamine treatment in older adults with psychiatric illness: a scoping review
Background: Ketamine, an N-methyl-D-aspartate antagonist, has been used for decades as an anesthetic agent, but more recently it has been studied in psychiatric illness. Though ketamine has been investigated for use in the general population, fewer studies have investigated the efficacy and tolerability of this treatment for older (age >60) adults. Objectives: This review sought to compile the randomized controlled trials (RCTs) investigating the evidence for ketamine treatment in older adults with psychiatric disorders. Eligibility criteria: Only RCTs published in English language journals, or with official English language translations, and human studies were included. Sources of evidence: Our team searched PubMed, Cochrane Database, and Ovid with the terms ketamine, depression, suicidal ideation, bipolar disorder, mania, anxiety, schizophrenia, psychotic disorders, dementia, delirium, and post-traumatic stress disorder. Charting methods: Covidence was used to extract and organize included studies. Results: Our review yielded 14 RCTs and 2 post-hoc analyses evaluating ketamine treatment in older patients. Eight of these studies examined ketamine for the treatment of delirium, while the remaining eight examined its use in depression. The studies had significant heterogeneity so direct comparisons of the results were challenging. However, five studies showed no significant impact of ketamine on delirium incidence. Two studies showed a lower incidence of delirium in the ketamine group, but another study showed a higher incidence of delirium with ketamine. Four studies showed improvement in depressive symptoms with ketamine treatment, while the others showed a lack of improvement. Most reported side effects were mild. Conclusion: Several studies have investigated ketamine for depression and delirium in older adults and show mixed results. This review reveals the paucity of current data on ketamine for other psychiatric conditions in older adults. It reaffirms that use of ketamine in older adults with psychiatric illness, including depression and delirium, remains an individual risk versus benefit analysis using shared decision making.
- 18 October 2025
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 16
Open AccessThe evidence for ketamine treatment in older adults with psychiatric illness: a scoping review
Background: Ketamine, an N-methyl-D-aspartate antagonist, has been used for decades as an anesthetic agent, but more recently it has been studied in psychiatric illness. Though ketamine has been investigated for use in the general population, fewer studies have investigated the efficacy and tolerability of this treatment for older (age >60) adults. Objectives: This review sought to compile the randomized controlled trials (RCTs) investigating the evidence for ketamine treatment in older adults with psychiatric disorders. Eligibility criteria: Only RCTs published in English language journals, or with official English language translations, and human studies were included. Sources of evidence: Our team searched PubMed, Cochrane Database, and Ovid with the terms ketamine, depression, suicidal ideation, bipolar disorder, mania, anxiety, schizophrenia, psychotic disorders, dementia, delirium, and post-traumatic stress disorder. Charting methods: Covidence was used to extract and organize included studies. Results: Our review yielded 14 RCTs and 2 post-hoc analyses evaluating ketamine treatment in older patients. Eight of these studies examined ketamine for the treatment of delirium, while the remaining eight examined its use in depression. The studies had significant heterogeneity so direct comparisons of the results were challenging. However, five studies showed no significant impact of ketamine on delirium incidence. Two studies showed a lower incidence of delirium in the ketamine group, but another study showed a higher incidence of delirium with ketamine. Four studies showed improvement in depressive symptoms with ketamine treatment, while the others showed a lack of improvement. Most reported side effects were mild. Conclusion: Several studies have investigated ketamine for depression and delirium in older adults and show mixed results. This review reveals the paucity of current data on ketamine for other psychiatric conditions in older adults. It reaffirms that use of ketamine in older adults with psychiatric illness, including depression and delirium, remains an individual risk versus benefit analysis using shared decision making.
- Open Access
- 15 October 2025
- Published by Elsevier in International Psychogeriatrics
- p. 100152
Social determinants of health associated with neuropsychiatric symptoms of dementia and mild cognitive impairment: A narrative review
- 15 October 2025
- Published by Elsevier in International Psychogeriatrics
- p. 100152
Open AccessSocial determinants of health associated with neuropsychiatric symptoms of dementia and mild cognitive impairment: A narrative review
- 3 May 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 281, 82-90
Psychosis associated with dementia: evaluation and management
- 3 May 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 281, 82-90
Psychosis associated with dementia: evaluation and management
- Open Access
- 3 March 2025
- Published by BioExcel in Drugs in Context
- Vol. 14, 1-6
Lecanemab for mild Alzheimer disease – is there a way forward?
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. The need for discussions regarding this medication as well as the importance of developing guidelines for use are also highlighted.
- 3 March 2025
- Published by BioExcel in Drugs in Context
- Vol. 14, 1-6
Open AccessLecanemab for mild Alzheimer disease – is there a way forward?
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. The need for discussions regarding this medication as well as the importance of developing guidelines for use are also highlighted.
- 14 November 2024
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 26 (6) , 57728
A Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia
The authors provide an updated summary of the literature on dextromethorphan-quinidine for the treatment of agitation in patients with dementia.
- 14 November 2024
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 26 (6) , 57728
A Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia
The authors provide an updated summary of the literature on dextromethorphan-quinidine for the treatment of agitation in patients with dementia.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 14
Geriatric psychiatry and brain health in old age
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 14
Open AccessGeriatric psychiatry and brain health in old age